Analysts Issue Forecasts for Xeris Biopharma FY2029 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Research analysts at HC Wainwright cut their FY2029 earnings estimates for shares of Xeris Biopharma in a note issued to investors on Friday, November 6th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.63 for the year, down from their prior estimate of $0.65. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.07 per share.

Several other equities research analysts have also issued reports on the company. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Barclays increased their price target on Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, October 6th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Oppenheimer reaffirmed an “outperform” rating and set a $21.00 price objective (up from $18.00) on shares of Xeris Biopharma in a research note on Friday. Finally, Leerink Partners boosted their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.20.

Xeris Biopharma Trading Up 4.3%

Shares of XERS stock opened at $15.86 on Monday. Xeris Biopharma has a 1 year low of $5.25 and a 1 year high of $15.94. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The stock’s 50 day simple moving average is $9.77 and its two-hundred day simple moving average is $7.66. The company has a market cap of $2.89 billion, a PE ratio of -317.14 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The company had revenue of $107.23 million during the quarter, compared to analyst estimates of $101.68 million.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 25,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the completion of the sale, the insider owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. This trade represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $12.49, for a total value of $312,250.00. Following the transaction, the insider owned 1,559,208 shares of the company’s stock, valued at $19,474,507.92. This trade represents a 1.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 173,332 shares of company stock valued at $1,721,471 in the last ninety days. 4.35% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Royce & Associates LP boosted its holdings in Xeris Biopharma by 27.5% during the 3rd quarter. Royce & Associates LP now owns 588,178 shares of the company’s stock valued at $5,623,000 after acquiring an additional 127,025 shares during the period. Knights of Columbus Asset Advisors LLC bought a new position in Xeris Biopharma in the 3rd quarter valued at $1,275,000. StoneX Group Inc. purchased a new stake in Xeris Biopharma in the third quarter worth $142,000. Pictet Asset Management Holding SA increased its stake in Xeris Biopharma by 13.7% in the third quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company’s stock worth $326,000 after purchasing an additional 4,108 shares during the period. Finally, AlphaCentric Advisors LLC increased its stake in Xeris Biopharma by 4.2% in the third quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock worth $464,000 after purchasing an additional 1,940 shares during the period. 42.75% of the stock is owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative.

The company also develops drug-delivery technologies intended to make medicines easier to store and administer.